U.S. market Closed. Opens in 17 hours 7 minutes

ALLR | Allarity Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 3.21 - 3.68
52 Week Range 2.5800 - 666.00
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 605,942
Average Volume 222,385
Shares Outstanding 1,412,650
Market Cap 4,774,757
Sector Healthcare
Industry Biotechnology
IPO Date 2021-12-21
Valuation
Profitability
Growth
Health
P/E Ratio -0.31
Forward P/E Ratio N/A
EPS -10.98
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 5
Country USA
Website ALLR
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
*Chart delayed
Analyzing fundamentals for ALLR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see ALLR Fundamentals page.

Watching at ALLR technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on ALLR Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙